Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANGIODYNAMICS INCANGO · Entity 5275 | Director | July 15, 2026 | July 23, 2026 |
| AVITA Medical, Inc.RCEL · Entity 5905 | Director | June 03, 2026 | June 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANGIODYNAMICS INC
Report date July 15, 2026 · Filed July 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 95,265 |
Reported balance
After 2026-07-15 transaction · row 1
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 11,887 · Balance 95,265 F1: The acquisition of 11,887 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") represents 11,887 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The acquisition of 11,887 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") represents 11,887 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant.
AVITA Medical, Inc.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,464 |
Last balance in matching sequence
After 2026-01-20 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2025-08-06 · Grant · Acquired 26,250 · Balance 26,250 F1: Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest in three equal annual installments on the date 12 months following the grant date of August 6, 2025. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026. F2: Includes unvested RSUs Row 2 · 2026-01-20 · Grant · Acquired 22,214 · Balance 48,464 F3: Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 20, 2026. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026. F2: Includes unvested RSUs |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.36 · Expires 2035-08-06 | Direct | 19,063 |
Reported balance
After 2025-08-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-08-06 · Grant · Acquired 19,063 · Balance 19,063 F4: On August 6, 2025, the Board of Directors approved a grant of 19,063 options to acquire 19,063 shares of Common Stock of the Company to Dr. Tarnoff as a new non-executive director, with an effective grant date of August 6, 2025 and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on August 6, 2025 of $5.36. The grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026. F5: These Stock Options vest in three equal annual installments beginning the first anniversary of the grant date. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.77 · Expires 2036-01-20 | Direct | 16,133 |
Reported balance
After 2026-01-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-20 · Grant · Acquired 16,133 · Balance 16,133 F6: On January 5, 2026, the Board of Directors approved a grant of 16,133 options to acquire 16,133 shares of Common Stock to each of its non-executive directors, with a grant date of January 20, 2026 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $3.77. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest in three equal annual installments on the date 12 months following the grant date of August 6, 2025. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.
F2: Includes unvested RSUs
F3: Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 20, 2026. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.
F4: On August 6, 2025, the Board of Directors approved a grant of 19,063 options to acquire 19,063 shares of Common Stock of the Company to Dr. Tarnoff as a new non-executive director, with an effective grant date of August 6, 2025 and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on August 6, 2025 of $5.36. The grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.
F5: These Stock Options vest in three equal annual installments beginning the first anniversary of the grant date.
F6: On January 5, 2026, the Board of Directors approved a grant of 16,133 options to acquire 16,133 shares of Common Stock to each of its non-executive directors, with a grant date of January 20, 2026 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $3.77. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2026 Filed Jul 23, 2026 00:06 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantCommon Stock | 11,887 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-029335 · form4.xml · nonDerivative · entry 1 Tarnoff Michael E · CIK 0001603289 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,265 F1 · shares: The acquisition of 11,887 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") represents 11,887 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant. Read SEC document |
| January 20, 2026 Filed Jun 4, 2026 23:09 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 16,133 | $0.00 Strike: $3.77 | $0.00 |
DisclosureSEC source: 0001603289-26-000002 · ownership.xml · derivative · entry 4 Tarnoff Michael E · CIK 0001603289 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,133 Underlying: Common Stock · 16,133 shares Expires 2036-01-20 F6 · derivative.exercise_price: On January 5, 2026, the Board of Directors approved a grant of 16,133 options to acquire 16,133 shares of Common Stock to each of its non-executive directors, with a grant date of January 20, 2026 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $3.77. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026. Read SEC document |
| January 20, 2026 Filed Jun 4, 2026 23:09 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 22,214 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001603289-26-000002 · ownership.xml · nonDerivative · entry 2 Tarnoff Michael E · CIK 0001603289 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,464 F3 · price: Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 20, 2026. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026. F2 · balance_after: Includes unvested RSUs Read SEC document |
| August 06, 2025 Filed Jun 4, 2026 23:09 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 19,063 | $0.00 Strike: $5.36 | $0.00 |
DisclosureSEC source: 0001603289-26-000002 · ownership.xml · derivative · entry 3 Tarnoff Michael E · CIK 0001603289 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,063 Underlying: Common Stock · 19,063 shares Expires 2035-08-06 F4 · derivative.exercise_price: On August 6, 2025, the Board of Directors approved a grant of 19,063 options to acquire 19,063 shares of Common Stock of the Company to Dr. Tarnoff as a new non-executive director, with an effective grant date of August 6, 2025 and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on August 6, 2025 of $5.36. The grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026. F5 · derivative.exercise_date: These Stock Options vest in three equal annual installments beginning the first anniversary of the grant date. Read SEC document |
| August 06, 2025 Filed Jun 4, 2026 23:09 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 26,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001603289-26-000002 · ownership.xml · nonDerivative · entry 1 Tarnoff Michael E · CIK 0001603289 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,250 F1 · price: Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest in three equal annual installments on the date 12 months following the grant date of August 6, 2025. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026. F2 · balance_after: Includes unvested RSUs Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 22:06 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantCommon Stock | 17,675 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-026457 · form4.xml · nonDerivative · entry 1 Tarnoff Michael E · CIK 0001603289 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,378 F1 · shares: The acquisition of 17,675 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") represents 17,675 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant. Read SEC document |
| July 17, 2024 Filed Jul 19, 2024 21:18 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantCommon Stock | 20,541 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-033636 · form4.xml · nonDerivative · entry 1 Tarnoff Michael E · CIK 0001603289 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,703 F1 · shares: The acquisition of 20,541 shares of common stock of AngioDynamics, Inc.("AngioDynamics") represents 20,541 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant. Read SEC document |
| July 19, 2023 Filed Jul 22, 2023 01:11 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantCommon Stock | 17,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-035720 · form4.xml · nonDerivative · entry 1 Tarnoff Michael E · CIK 0001603289 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,162 F1 · shares: The acquisition of 17,041 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") represents 17,041 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant. Read SEC document |
| July 20, 2022 Filed Jul 22, 2022 22:20 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantCommon Stock | 7,060 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-014363 · doc1.xml · nonDerivative · entry 1 Tarnoff Michael E · CIK 0001603289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,121 F1 · shares: The acquisition of 7,060 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 7,060 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/20/2023. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 22:40 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantCommon Stock | 5,738 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013915 · doc1.xml · nonDerivative · entry 1 Tarnoff Michael E · CIK 0001603289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,061 F1 · shares: The acquisition of 5,738 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 5,738 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/21/2022. Read SEC document |
| July 14, 2020 Filed Sep 16, 2020 20:17 UTC | ANGIODYNAMICS INC ANGO · Entity 5275 | GrantCommon Stock | 15,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-016796 · doc1.xml · nonDerivative · entry 1 Tarnoff Michael E · CIK 0001603289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,323 F1 · shares: The acquisition of 15,323 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 15,323 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/14/2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.